Renato Martins

16.1k total citations · 2 hit papers
81 papers, 4.0k citations indexed

About

Renato Martins is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Otorhinolaryngology. According to data from OpenAlex, Renato Martins has authored 81 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Pulmonary and Respiratory Medicine, 46 papers in Oncology and 21 papers in Otorhinolaryngology. Recurrent topics in Renato Martins's work include Lung Cancer Treatments and Mutations (45 papers), Head and Neck Cancer Studies (21 papers) and Lung Cancer Diagnosis and Treatment (16 papers). Renato Martins is often cited by papers focused on Lung Cancer Treatments and Mutations (45 papers), Head and Neck Cancer Studies (21 papers) and Lung Cancer Diagnosis and Treatment (16 papers). Renato Martins collaborates with scholars based in United States, Taiwan and Brazil. Renato Martins's co-authors include Keith D. Eaton, Julie E. Bauman, Lecia V. Sequist, Shirish M. Gadgeel, Amit Panwalkar, Steven Powell, Shadia I. Jalal, Ryan D. Gentzler, Amita Patnaik and Matthew A. Gubens and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Renato Martins

77 papers receiving 3.9k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

2016 1.1k citations Corey J. Langer, Shirish M. Gadgeel et al. The Lancet Oncology profile →
Managing Cancer Care During the COVID-19 Pandemic: Agility and Collaboration Toward a Common Goal

2020 367 citations Renato Martins, F. Marc Stewart et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Renato Martins United States	24	2.6k	1.7k	811	452	445	81	4.0k
William N. William United States	33	2.0k 0.8×	1.5k 0.9×	893 1.1×	173 0.4×	559 1.3×	109	4.0k
Francisco Vera-Badillo Canada	27	3.4k 1.3×	1.6k 0.9×	754 0.9×	162 0.4×	1.2k 2.8×	76	5.5k
Laura Meyer United States	9	2.0k 0.7×	1.6k 0.9×	653 0.8×	250 0.6×	803 1.8×	12	4.6k
Douglas B. Flieder United States	35	2.0k 0.8×	2.6k 1.5×	801 1.0×	168 0.4×	555 1.2×	86	5.2k
Jimmy J. Hwang United States	32	2.5k 1.0×	814 0.5×	940 1.2×	166 0.4×	637 1.4×	159	4.2k
Sylvie Chabaud France	35	1.6k 0.6×	2.3k 1.3×	782 1.0×	115 0.3×	600 1.3×	191	5.6k
Daniel R. Gomez United States	47	3.1k 1.2×	4.3k 2.5×	815 1.0×	344 0.8×	834 1.9×	260	8.1k
Yee Ung Canada	32	2.1k 0.8×	2.8k 1.6×	880 1.1×	139 0.3×	509 1.1×	94	5.1k
Eli Rosenbaum Israel	34	1.0k 0.4×	972 0.6×	1.7k 2.1×	787 1.7×	655 1.5×	112	3.6k
Wallace Akerley United States	36	2.7k 1.0×	3.1k 1.8×	1.1k 1.3×	94 0.2×	489 1.1×	156	5.2k

Countries citing papers authored by Renato Martins

Since Specialization

Citations

This map shows the geographic impact of Renato Martins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Renato Martins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Renato Martins more than expected).

Fields of papers citing papers by Renato Martins

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Renato Martins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Renato Martins. The network helps show where Renato Martins may publish in the future.

Co-authorship network of co-authors of Renato Martins

This figure shows the co-authorship network connecting the top 25 collaborators of Renato Martins. A scholar is included among the top collaborators of Renato Martins based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Renato Martins. Renato Martins is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Voutsinas, Jenna, Jonathan R. Fromm, Renato Martins, et al.. (2024). Long term outcomes in patients with recurrent/metastatic (R/M) salivary gland cancer (SGC) treated with immune checkpoint inhibitors (ICI).. Journal of Clinical Oncology. 42(16_suppl). e18063–e18063. 1 indexed citations

Araujo, André, et al.. (2024). XFeat: Accelerated Features for Lightweight Image Matching. 2682–2691. 39 indexed citations

Rodriguez, Cristina P., Vicky Wu, Jenna Voutsinas, et al.. (2023). Dual PD1 and CTLA4 immune checkpoint blockade and hypofractionated radiation in patients with salivary gland cancers.. Journal of Clinical Oncology. 41(16_suppl). 6011–6011. 1 indexed citations

Eaton, Keith D., et al.. (2021). Impact of Clinical Trial Participation on Survival of Patients with Metastatic Non-Small Cell Lung Cancer. Clinical Lung Cancer. 22(6). 523–530. 6 indexed citations

Bowen, Stephen R., Daniel S. Hippe, Hannah Thomas, et al.. (2021). Prognostic Value of Early Fluorodeoxyglucose-Positron Emission Tomography Response Imaging and Peripheral Immunologic Biomarkers: Substudy of a Phase II Trial of Risk-Adaptive Chemoradiation for Unresectable Non-Small Cell Lung Cancer. Advances in Radiation Oncology. 7(2). 100857–100857. 3 indexed citations

Martins, Renato, Bruno M. Costa, Cláudia Carvalho, et al.. (2020). Prognostic Factors After Hepatectomy for Gastric Adenocarcinoma Liver Metastases: Desmoplastic Growth Pattern as the Key to Improved Overall Survival. SHILAP Revista de lepidopterología.

Rodriguez, Cristina P., Qian Wu, Jenna Voutsinas, et al.. (2019). A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer. Clinical Cancer Research. 26(4). 837–845. 135 indexed citations

Méndez, Eduardo, Cristina P. Rodriguez, Michael Kao, et al.. (2018). A Phase I Clinical Trial of AZD1775 in Combination with Neoadjuvant Weekly Docetaxel and Cisplatin before Definitive Therapy in Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research. 24(12). 2740–2748. 79 indexed citations

Méndez, Eduardo, Cristina P. Rodriguez, Michael Kao, et al.. (2017). A phase I clinical trial of AZD1775 in combination with neoadjuvant weekly cisplatin and docetaxel in borderline resectable head and neck squamous cell carcinoma (HNSCC).. Journal of Clinical Oncology. 35(15_suppl). 6034–6034. 2 indexed citations

10.

Panattoni, Laura, Catherine R. Fedorenko, Karma L. Kreizenbeck, et al.. (2017). The role of chronic disease in the costs of potentially preventable emergency department use during treatment: A regional study.. Journal of Clinical Oncology. 35(15_suppl). 6505–6505. 1 indexed citations

11.

Chow, Laura Q.M., Chihiro Morishima, Keith D. Eaton, et al.. (2016). Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN. Clinical Cancer Research. 23(10). 2442–2450. 100 indexed citations

12.

Langer, Corey J., Shirish M. Gadgeel, Hossein Borghaei, et al.. (2016). Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. The Lancet Oncology. 17(11). 1497–1508. 1071 indexed citations breakdown →

13.

Kreizenbeck, Karma L., Lotte Steuten, Veena Shankaran, et al.. (2016). Value in cancer care: Regional initiative to improve care through data reporting and interventions.. Journal of Clinical Oncology. 34(7_suppl). 34–34. 1 indexed citations

14.

Rodriguez, Cristina P., Upendra Parvathaneni, Eduardo Méndez, & Renato Martins. (2015). Salivary Gland Malignancies. Hematology/Oncology Clinics of North America. 29(6). 1145–1157. 4 indexed citations

15.

Bauman, Julie E., Melissa Austin, Brenda F. Kurland, et al.. (2013). ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial. British Journal of Cancer. 109(8). 2096–2105. 46 indexed citations

16.

Austin, Melissa, Rodney A. Schmidt, Upendra Parvathaneni, et al.. (2012). Expression of p16, ERCC1, and EGFR amplification as predictors of responsiveness of locally advanced squamous cell carcinomas of head and neck (SCCHN) to cisplatin, radiotherapy, and erlotinib: A phase II randomized trial.. Journal of Clinical Oncology. 30(15_suppl). 5515–5515. 6 indexed citations

17.

Schlumberger, Martin, Barbara Jarząb, Maria E. Cabanillas, et al.. (2012). A phase II trial of the multitargeted kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer (MTC).. Journal of Clinical Oncology. 30(15_suppl). 5591–5591. 25 indexed citations

18.

Bauman, Julie E., Keith D. Eaton, Laurie L. Carr, et al.. (2012). A Phase II study of pulse dose imatinib mesylate and weekly paclitaxel in patients aged 70 and over with advanced non-small cell lung cancer. BMC Cancer. 12(1). 449–449. 25 indexed citations

19.

Till, Brian G. & Renato Martins. (2007). Response to paclitaxel in adenoid cystic carcinoma of the salivary glands. Head & Neck. 30(6). 810–814. 6 indexed citations

20.

Martins, Renato. (2005). Treatment of Locally Advanced Non-Small Cell Lung Cancer with Combination of Chemotherapy and Radiation. Seminars in Respiratory and Critical Care Medicine. 26(3). 273–277. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact